supp.fit

Vitamin E, Copper, Zinc, Beta-Carotene and Vitamin C: study protocols

6 study groups took Vitamin E together with Copper, Zinc, Beta-Carotene and Vitamin C. These are the doses the studies gave. They are not a recommendation.

Vitamin E: what the research found →

Dose per serving from research: Vitamin E

5 study groups in 3 studies say how much Vitamin E participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 IU to 500 IU, 100% of 5 study groups.

Daily doseStudy groups
250 IU to 500 IU
5

Dose per serving from research: Zinc

6 study groups in 4 studies say how much Zinc participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 50 mg to 100 mg, 83% of 6 study groups.

Daily doseStudy groups
25 mg or less
1
25 mg to 50 mg
0
50 mg to 100 mg
5

Dose per serving from research: Beta-Carotene

6 study groups in 4 studies say how much Beta-Carotene participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 10 mg to 25 mg, 100% of 6 study groups.

Daily doseStudy groups
10 mg to 25 mg
6

Dose per serving from research: Vitamin C

6 study groups in 4 studies say how much Vitamin C participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg, 100% of 6 study groups.

Daily doseStudy groups
250 mg to 500 mg
6

Commonly used together

None of these 6 study groups took Vitamin E, Copper, Zinc, Beta-Carotene and Vitamin C with anything else.

6 study groups

Study
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye
400 IU2 mg80 mg15 mg500 mg8 years—
No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38
2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years
400 IU2 mg80 mg15 mg500 mg9 years—
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men
400 mg—69.6 mg17.2 mg452 mg1 day15
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration
400 IU2 mg80 mg15 mg500 mg5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
400 IU2 mg80 mg15 mg500 mg5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
400 IU—25 mg15 mg500 mg5 years—